Sweden · Delayed Price · Currency is SEK Medivir AB Statistics
Total Valuation
Medivir AB has a market cap or net worth of SEK 1.22 billion. The enterprise value is 973.28 million.
| Market Cap | 1.22B |
| Enterprise Value | 973.28M |
Important Dates
The last earnings date was Thursday, August 20, 2026.
| Earnings Date | Aug 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Medivir AB has 617.94 million shares outstanding. The number of shares has increased by 203.20% in one year.
| Current Share Class | 617.94M |
| Shares Outstanding | 617.94M |
| Shares Change (YoY) | +203.20% |
| Shares Change (QoQ) | +17.96% |
| Owned by Insiders (%) | 20.20% |
| Owned by Institutions (%) | 15.89% |
| Float | 341.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 38.26 |
| PS Ratio | 140.40 |
| PB Ratio | 4.13 |
| P/TBV Ratio | 4.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 111.79 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.49, with a Debt / Equity ratio of 0.02.
| Current Ratio | 8.49 |
| Quick Ratio | 8.49 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.09 |
| Interest Coverage | -37.44 |
Financial Efficiency
Return on equity (ROE) is -46.51% and return on invested capital (ROIC) is -182.06%.
| Return on Equity (ROE) | -46.51% |
| Return on Assets (ROA) | -22.63% |
| Return on Invested Capital (ROIC) | -182.06% |
| Return on Capital Employed (ROCE) | -28.79% |
| Weighted Average Cost of Capital (WACC) | 5.01% |
| Revenue Per Employee | 1.45M |
| Profits Per Employee | -14.55M |
| Employee Count | 6 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1.13% in the last 52 weeks. The beta is 0.11, so Medivir AB's price volatility has been lower than the market average.
| Beta (5Y) | 0.11 |
| 52-Week Price Change | +1.13% |
| 50-Day Moving Average | 1.79 |
| 200-Day Moving Average | 1.44 |
| Relative Strength Index (RSI) | 58.02 |
| Average Volume (20 Days) | 2,112,211 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Medivir AB had revenue of SEK 8.71 million and -87.30 million in losses. Loss per share was -0.26.
| Revenue | 8.71M |
| Gross Profit | -31.91M |
| Operating Income | -86.57M |
| Pretax Income | -87.30M |
| Net Income | -87.30M |
| EBITDA | -87.28M |
| EBIT | -86.57M |
| Loss Per Share | -0.26 |
Balance Sheet
The company has 253.50 million in cash and 4.50 million in debt, with a net cash position of 249.00 million or 0.40 per share.
| Cash & Cash Equivalents | 253.50M |
| Total Debt | 4.50M |
| Net Cash | 249.00M |
| Net Cash Per Share | 0.40 |
| Equity (Book Value) | 295.80M |
| Book Value Per Share | 0.48 |
| Working Capital | 228.50M |
Cash Flow
| Operating Cash Flow | -51.65M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | -715,000 |
| Net Borrowing | -32.68M |
| Free Cash Flow | -51.65M |
| FCF Per Share | -0.08 |
Margins
| Gross Margin | n/a |
| Operating Margin | -994.36% |
| Pretax Margin | -1,002.76% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Medivir AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -203.20% |
| Shareholder Yield | -203.20% |
| Earnings Yield | -7.14% |
| FCF Yield | -4.23% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Medivir AB has an Altman Z-Score of 4.05 and a Piotroski F-Score of 4.
| Altman Z-Score | 4.05 |
| Piotroski F-Score | 4 |